Wednesday, July 8, 2026

pharma · Hemophilia A With Inhibitor · Hemophilia A · CPRX

CATALYST PHARMACEUTICALS

Catalyst Pharmaceuticals is a pharma organization headquartered in Coral Gables, USA. It trades on NYSE under ticker CPRX. Primary therapeutic focus areas include Hemophilia A With Inhibitor, Hemophilia A, Hemophilia B,

355 Alhambra Circle, Suite 801, Coral Gables, Florida 33134, US HQ
2002 Founded
179 Employees
Public company Type
CPRX · NYSE Ticker
Company details
Status
Public
HQ
355 Alhambra Circle, Suite 801, Coral Gables, Florida 33134, US
Founded
2002
Employees
179
Programs
23
Drugs
20
Patents
61
Clinical program

Amifampridine Phosphate 10 MG Oral Tablet

Phase 2 · small molecule · Spinal Muscular Atrophy Type 3

Amifampridine Phosphate 10 MG Oral Tablet for Spinal Muscular Atrophy Type 3 is a Phase 2 program (small_molecule) at CATALYST PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

← All CATALYST PHARMACEUTICALS, INC. projects Phase 2 small molecule terminated

Internal code SMA-002

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
CATALYST PHARMACEUTICALS, INC.
Phase
Phase 2
Modality
small_molecule
Indication
Spinal Muscular Atrophy Type 3
Status
terminated
Trials
1